Navigation Links
Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection
Date:5/7/2008

WOODCLIFF LAKE, N.J., May 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it amended its agreement with Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) for $20 million in cash to increase its share of profits from the generic versions of GlaxoSmithKline's Imitrex(R) Injection, which will be immediately accretive to 2008 earnings and provide a strong return on the Company's investment. As a result of the agreement, Par's profit share will increase from 38% to 95% from the commercialization of sumatriptan injection. Imitrex Injection (sumatriptan succinate injection) is used for the acute treatment of migraine attacks with or without aura, and the acute treatment of cluster headache episodes. Annual US sales of Imitrex Injection are approximately $220 million, according to IMS Health.

In February 2006, Par entered into a collaborative agreement with Spectrum to develop and market generic drugs, including sumatriptan injection. In November 2006, Spectrum entered into a settlement agreement with GlaxoSmithKline (GSK) that resolved US patent litigation related to GSK's Imitrex Injection. Par is permitted to sell generic versions of the 4mg and 6mg starter kits and the 4mg and 6mg prefilled syringe cartridges with an expected launch date no later than November 2008, which is three months before the compound patent expires in February 2009. Par has also acquired Spectrum's remaining interest for the right to sell the 6mg vials.

"We are pleased to add the full line of sumatriptan injectable products to our generic portfolio," said Paul Campanelli, president of Par's generic division. "Patients suffering from migraines will soon have a familiar and more affordable option available to them."

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to risks and uncertainties, including the extent and impact of litigation arising out of the accounting issues described in the Company's filings with the Securities and Exchange Commission (SEC), the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against the Company, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the SEC, such as the Company's reports on Form 10-K, Form 10-Q and Form 8-K, and amendments thereto. Any forward-looking statements included in this press release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
2. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
3. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
4. Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM
5. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
6. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
7. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
9. West Pharmaceutical Services, Inc. Announces Annual Meeting Webcast
10. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
11. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Florida (PRWEB) , ... January 19, 2017 , ... ... dollar 5,000 SF expansion and facility enhancement of their 503A compounding pharmacy located ... meet the growing demand of physicians and patients throughout the United States for ...
(Date:1/19/2017)... , ... January 19, 2017 , ... WhoHaha , ... up with the American Heart Association (AHA) to produce a three-part video series that ... will debut as part of the launch of AHA’s Healthy For Good™ movement, which ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it will be co-hosting a ... innovative excipients and drug delivery solutions to health industries worldwide. The one day ...
(Date:1/19/2017)... ... January 19, 2017 , ... In ... administered fillers that resulted in severe facial disfiguration. After four frightening years of ... doctors at UCLA Medical Center, who removed the substances in a partial facial ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) is ... passionate about making a difference in the lives of the next generation of ... nonprofit healthcare educational institution, has more than 30,000 alumni and employs more than ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
(Date:1/19/2017)... BOCA RATON, Fla. , Jan. 19, 2017 ... ), a medical device company specializing in the ... conditions, such as keloids, with superficial radiation therapy, ... quarter and full year 2016 financial results on Thursday, ... The Company will hold a conference call ...
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
Breaking Medicine Technology: